I think the HY report reminded everyone of the cash rate burn.. some $4.2M for the 6 months with a net loss for the 6 months of $2.4M .
The biotech industry is a slow moving beast and fairly expensive to run, many investors hoping for a quick return will , imo , be likely to leave.
This company is one to hold on to , with a CR of $15M at 11c , they are funded for the foreseeable future.
I still think the company will not reach it's full potential for awhile yet.
The impatient will move on.
Ann: Half Yearly Report and Accounts, page-26
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $672.4M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 38.0¢ | 36.5¢ | $993.3K | 2.673M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 278064 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 25974 | 2 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |